KR101951220B1 - 조합 als 치료법 - Google Patents

조합 als 치료법 Download PDF

Info

Publication number
KR101951220B1
KR101951220B1 KR1020147000783A KR20147000783A KR101951220B1 KR 101951220 B1 KR101951220 B1 KR 101951220B1 KR 1020147000783 A KR1020147000783 A KR 1020147000783A KR 20147000783 A KR20147000783 A KR 20147000783A KR 101951220 B1 KR101951220 B1 KR 101951220B1
Authority
KR
South Korea
Prior art keywords
riluzole
administered
delete delete
composition
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020147000783A
Other languages
English (en)
Korean (ko)
Other versions
KR20140074270A (ko
Inventor
제시 세달바움
존 마오
패디 말릭
앤드류 에이. 울프
Original Assignee
싸이토키네틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 싸이토키네틱스, 인코포레이티드 filed Critical 싸이토키네틱스, 인코포레이티드
Publication of KR20140074270A publication Critical patent/KR20140074270A/ko
Application granted granted Critical
Publication of KR101951220B1 publication Critical patent/KR101951220B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020147000783A 2011-07-13 2012-07-12 조합 als 치료법 Expired - Fee Related KR101951220B1 (ko)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201161507381P 2011-07-13 2011-07-13
US61/507,381 2011-07-13
US201161544533P 2011-10-07 2011-10-07
US61/544,533 2011-10-07
US201261637770P 2012-04-24 2012-04-24
US201261637759P 2012-04-24 2012-04-24
US61/637,759 2012-04-24
US61/637,770 2012-04-24
US201261646699P 2012-05-14 2012-05-14
US61/646,699 2012-05-14
PCT/US2012/046523 WO2013010015A2 (en) 2011-07-13 2012-07-12 Combination als therapy

Publications (2)

Publication Number Publication Date
KR20140074270A KR20140074270A (ko) 2014-06-17
KR101951220B1 true KR101951220B1 (ko) 2019-02-22

Family

ID=47506929

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147000783A Expired - Fee Related KR101951220B1 (ko) 2011-07-13 2012-07-12 조합 als 치료법

Country Status (16)

Country Link
US (1) US10272082B2 (enExample)
EP (1) EP2731611B1 (enExample)
JP (2) JP6145946B2 (enExample)
KR (1) KR101951220B1 (enExample)
CN (2) CN104039148A (enExample)
AU (2) AU2012281042B2 (enExample)
BR (1) BR112014000742A2 (enExample)
CA (1) CA2849213A1 (enExample)
EA (2) EA028060B1 (enExample)
HK (1) HK1197178A1 (enExample)
IL (1) IL230391B (enExample)
IN (1) IN2014DN00200A (enExample)
PH (1) PH12014500094A1 (enExample)
SG (1) SG10201605707UA (enExample)
WO (1) WO2013010015A2 (enExample)
ZA (1) ZA201400236B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
US20160263110A1 (en) * 2013-11-04 2016-09-15 Ab Science Use of masitinib for treatment of amyotrophic lateral sclerosis
EP3137622B1 (en) * 2014-04-29 2021-11-24 Cytokinetics, Inc. Methods of reducing decline in vital capacity
EA201791110A1 (ru) * 2014-11-21 2017-11-30 Биохэвен Фармасьютикэл Холдинг Компани Лтд. Сублингвальное введение рилузола
LT3220891T (lt) 2014-11-21 2019-11-11 Biohaven Therapeutics Ltd Poliežuvinė riluzolio kompozicija
EP3072513A1 (en) * 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis
SG11201808106YA (en) 2016-03-25 2018-10-30 Ab Science Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
EP4031135A4 (en) 2019-09-20 2023-10-18 Icahn School of Medicine at Mount Sinai CONTROLLED RELEASE FORMULATIONS OF RILUZOLE AND USES THEREOF

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3507866A (en) 1967-08-08 1970-04-21 Merck & Co Inc 1h - imidazo(4,5-b)pyrazin - 2 - one and processes for their preparation
BE788065A (fr) 1971-08-26 1973-02-26 Degussa Nouvelles aza-benzimidazoles et procede pour leur preparation
IT1156732B (it) 1978-05-10 1987-02-04 Roussel Maestretti Spa Derivati sostituiti dell'1,3-diidroimidazo(4,5-b)piridin-2-one e relativo procedimento di produzione
US4668686A (en) 1985-04-25 1987-05-26 Bristol-Myers Company Imidazoquinoline antithrombrogenic cardiotonic agents
US4775674A (en) 1986-05-23 1988-10-04 Bristol-Myers Company Imidazoquinolinylether derivatives useful as phosphodiesterase and blood aggregation inhibitors
US4943573A (en) 1989-11-01 1990-07-24 Bristol-Myers Squibb Company Imidazo[4,5-b]quinolinyloxyalkanoic acid amides with enhanced water solubility
US5354759A (en) 1991-09-12 1994-10-11 Fujisawa Pharmaceutical Co., Ltd. Angiotenin II antagonizing heterocyclic compounds
JPH0641135A (ja) 1992-07-21 1994-02-15 Nippon Soda Co Ltd イミダゾプテリジン誘導体及びその製造方法
US6162804A (en) 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
IL139811A0 (en) 1998-06-04 2002-02-10 Abbott Lab Cell adhesion-inhibiting antinflammatory compounds
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
EP1218383B1 (de) 1999-10-08 2008-11-05 Grünenthal GmbH Bicyclische imidazo-5-yl-aminderivate
AU779197B2 (en) 1999-10-08 2005-01-13 Grunenthal Gmbh Bicyclic imidazo-3-yl-amine derivatives
DE10050663A1 (de) 2000-10-13 2002-04-18 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung
US20030083318A1 (en) * 2001-10-25 2003-05-01 Jean-Pierre Julien Therapy for neurodegenerative diseases
US20040235801A1 (en) * 2001-10-25 2004-11-25 Jean-Pierre Julien Therapy for stroke
GB0206860D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
GB0212048D0 (en) 2002-05-24 2002-07-03 Merck Sharp & Dohme Therapeutic agents
AU2003294249A1 (en) 2002-11-08 2004-06-03 Trimeris, Inc. Hetero-substituted benzimidazole compounds and antiviral uses thereof
GB2400101A (en) 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
US7476665B2 (en) 2003-06-26 2009-01-13 Merck & Co., Inc. Benzodiazepine CGRP receptor antagonists
US20060148805A1 (en) 2003-07-01 2006-07-06 Meng Hsin Chen Opthalmic compositions for treating ocular hypertension
CA2550091A1 (en) 2003-12-19 2005-07-07 Elixir Pharmaceuticals, Inc. Methods of treating a disorder
EP1715855A4 (en) 2004-01-29 2010-06-16 Elixir Pharmaceuticals Inc ANTIVIRAL DRUGS
WO2005108374A1 (en) 2004-04-29 2005-11-17 Fmc Corporation Insecticidal diazole and triazole derivatives
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
EP1796467A4 (en) 2004-09-24 2009-07-01 Janssen Pharmaceutica Nv INHIBITORS IMIDAZO {4,5-B} PYRAZINONE PROTEIN KINASES
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
US7763616B2 (en) 2005-02-16 2010-07-27 Schering Corporation Piperazine-piperidines with CXCR3 antagonist activity
EP1959962A2 (en) 2005-12-16 2008-08-27 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
WO2007125321A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
US20090082370A1 (en) 2006-04-25 2009-03-26 Neil Thomas Thompson Pharmaceutical Combinations of PK Inhibitors and Other Active Agents
US8227603B2 (en) 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
US20100173930A1 (en) 2006-08-01 2010-07-08 Alex Muci Certain Chemical Entities, Compositions and Methods
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
SI2583970T1 (sl) * 2006-08-02 2016-03-31 Cytokinetics, Inc. Določene kemijske enote, sestavki in postopki, ki obsegajo imidazopirimidine
EP2666777A1 (en) * 2006-08-02 2013-11-27 Cytokinetics, Inc. Certain chemical entities having an imidazo<4,5-b>pyrazin-2(3H)-one core, compositions and methods
NZ576278A (en) 2006-10-19 2011-12-22 Signal Pharm Llc Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
CL2007002994A1 (es) 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
WO2008075007A1 (en) 2006-12-21 2008-06-26 Cancer Research Technology Limited Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents
AU2008206045A1 (en) 2007-01-19 2008-07-24 Ardea Biosciences, Inc. Inhibitors of MEK
EP2139478A4 (en) 2007-03-30 2010-05-05 Cytokinetics Inc CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
EP2018854A1 (en) * 2007-07-27 2009-01-28 Merz Pharma GmbH & Co. KGaA Novel combinations of neramexane for the treatment of neurodegenerative disorders
MX2010008518A (es) 2008-02-04 2010-11-10 Cytokinetics Inc Ciertas entidades quimicas, composiciones y metodos.
US7998976B2 (en) 2008-02-04 2011-08-16 Cytokinetics, Inc. Certain chemical entities, compositions and methods
US20110268729A1 (en) * 2008-07-11 2011-11-03 Bams Abila Treatment of amyotrophic lateral sclerosis by nogo-a-antagonist
CN102264743B (zh) 2008-11-25 2015-02-11 罗彻斯特大学 Mlk抑制剂及其使用方法
EP2228054A1 (en) * 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Riluzole aqueous suspensions
AU2010262970A1 (en) * 2009-06-19 2012-01-12 Knopp Neurosciences, Inc. Compositions and methods for treating amyotrophic lateral sclerosis
AU2013243671B2 (en) 2012-04-02 2017-09-21 Cytokinetics, Inc. Methods for improving diaphragm function
CN104395458A (zh) 2012-04-11 2015-03-04 赛特凯恩蒂克公司 改善对骨骼肌疲劳的抵抗力
EP3137622B1 (en) 2014-04-29 2021-11-24 Cytokinetics, Inc. Methods of reducing decline in vital capacity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Lancet Neurol, 10, 481-490쪽(2011.05.)*

Also Published As

Publication number Publication date
CN109316480A (zh) 2019-02-12
EP2731611A4 (en) 2015-02-18
JP2017128610A (ja) 2017-07-27
CA2849213A1 (en) 2013-01-17
JP2014520856A (ja) 2014-08-25
AU2012281042A1 (en) 2014-01-30
PH12014500094A1 (en) 2014-03-17
SG10201605707UA (en) 2016-09-29
IL230391B (en) 2019-03-31
KR20140074270A (ko) 2014-06-17
JP6145946B2 (ja) 2017-06-14
AU2012281042B2 (en) 2016-07-14
US20140243344A1 (en) 2014-08-28
WO2013010015A2 (en) 2013-01-17
NZ619924A (en) 2016-02-26
EA028060B1 (ru) 2017-10-31
WO2013010015A3 (en) 2014-05-15
BR112014000742A2 (pt) 2016-08-23
CN104039148A (zh) 2014-09-10
IN2014DN00200A (enExample) 2015-06-05
EA201490011A1 (ru) 2014-08-29
EA201791043A1 (ru) 2017-09-29
AU2016244263A1 (en) 2016-11-03
HK1197178A1 (en) 2015-01-09
US10272082B2 (en) 2019-04-30
EP2731611B1 (en) 2019-09-18
EP2731611A2 (en) 2014-05-21
ZA201400236B (en) 2014-10-29

Similar Documents

Publication Publication Date Title
KR101951220B1 (ko) 조합 als 치료법
JP2022171808A (ja) リポソームイリノテカン、オキサリプラチン、５－フルオロウラシル（およびロイコボリン）を含む併用療法を用いる胃がんの処置
KR102860817B1 (ko) 트라디피턴트에 의한 치료 방법
US20120157472A1 (en) Method for treating colorectal cancer
BRPI0616344A2 (pt) mÉtodo para o tratamento de dependÊncia quÍmica e comportamental
KR102624627B1 (ko) 지연 방출 데페리프론 정제 및 그의 사용 방법
CN106999467A (zh) 治疗认知减退的方法
AU2022252766B2 (en) Treatment of hand eczema
JP2024019691A (ja) 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法
US20040152625A1 (en) Method for improving the pharmacokinetics of an NNRTI
KR20220008893A (ko) 피부 홍반성 루푸스의 치료
US7998973B2 (en) Tivozanib and temsirolimus in combination
TW201806599A (zh) 用於快速開始抗抑鬱作用之給藥方案
JP6420923B1 (ja) 医薬
KR100709531B1 (ko) 당뇨병성 합병증의 예방 또는 진전저지용 의약조성물
US20250152566A1 (en) Use of aminopyridine, in particular amifampridine, for the treatment of a virally-associated fatigue
MX2014000455A (es) Terapia de combinacion para esclerosis lateral amiotrofica.
NZ619924B2 (en) Combination als therapy
WO2021057661A1 (zh) 一种降糖药物组合物
HK40009222A (en) Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)
TW201919704A (zh) 利用吡啶斯的明（pyridostigmine）及nk-1拮抗劑治療重症肌無力之醫藥組合物及方法
HK1248552B (en) Method of treatment with tradipitant

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20220219

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20220219